Altimmune, Inc. (ALT)
3.035
+0.10
(+3.23%)
USD |
NASDAQ |
Jun 30, 16:00
3.035
0.00 (0.00%)
After-Hours: 18:46
Altimmune Enterprise Value : 87.12M for June 29, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 29, 2026 | 87.12M |
| June 26, 2026 | 71.49M |
| June 25, 2026 | 78.00M |
| June 24, 2026 | 88.42M |
| June 23, 2026 | 83.21M |
| June 22, 2026 | 85.81M |
| June 18, 2026 | 55.86M |
| June 17, 2026 | 48.05M |
| June 16, 2026 | 45.44M |
| June 15, 2026 | 48.05M |
| June 12, 2026 | 44.14M |
| June 11, 2026 | 41.54M |
| June 10, 2026 | 44.14M |
| June 09, 2026 | 50.65M |
| June 08, 2026 | 59.77M |
| June 05, 2026 | 57.16M |
| June 04, 2026 | 84.51M |
| June 03, 2026 | 78.00M |
| June 02, 2026 | 81.91M |
| June 01, 2026 | 96.23M |
| May 29, 2026 | 101.44M |
| May 28, 2026 | 104.04M |
| May 27, 2026 | 92.32M |
| May 26, 2026 | 85.81M |
| May 22, 2026 | 81.91M |
| Date | Value |
|---|---|
| May 21, 2026 | 85.81M |
| May 20, 2026 | 71.49M |
| May 19, 2026 | 61.07M |
| May 18, 2026 | 68.88M |
| May 15, 2026 | 75.40M |
| May 14, 2026 | 84.51M |
| May 13, 2026 | 97.53M |
| May 12, 2026 | 105.35M |
| May 11, 2026 | 106.65M |
| May 08, 2026 | 106.65M |
| May 07, 2026 | 100.14M |
| May 06, 2026 | 128.79M |
| May 05, 2026 | 102.74M |
| May 04, 2026 | 97.53M |
| May 01, 2026 | 71.49M |
| April 30, 2026 | 42.84M |
| April 29, 2026 | 46.75M |
| April 28, 2026 | 61.07M |
| April 27, 2026 | 68.88M |
| April 24, 2026 | 75.40M |
| April 23, 2026 | 80.60M |
| April 22, 2026 | 156.13M |
| April 21, 2026 | 148.32M |
| April 20, 2026 | 167.85M |
| April 17, 2026 | 160.04M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Agenus, Inc. | 384.05M |
| Amgen, Inc. | 239.87B |
| Halozyme Therapeutics, Inc. | 10.97B |
| Protalix Biotherapeutics, Inc. | 146.03M |
| Humacyte, Inc. | 194.59M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -22.56M |
| Total Expenses (Quarterly) | 22.56M |
| EPS Diluted (Quarterly) | -0.1813 |
| Earnings Yield | -30.89% |
| Normalized Earnings Yield | -30.89 |